Jaros D, Bozic B, Sebesta C. [Gastrointestinal stromal tumors (GIST)]. Wien Med Wochenschr 2022.
Davila RE. A gastroenterologist’s Approach to the diagnosis and management of gastrointestinal stromal tumors. Gastroenterol Clin North Am. 2022;51(3):609–24.
Gao X, Xue A, Fang Y, Shu P, Ling J, Qin J, Hou Y, Shen K, Sun Y, Qin X. Role of Surgery in patients with focally Progressive gastrointestinal stromal tumors resistant to imatinib. Sci Rep. 2016;6:22840.
Corless CL. Gastrointestinal stromal tumors: what do we know now? Mod Pathol. 2014;27(Suppl 1):1–16.
Mei L, Smith SC, Faber AC, Trent J, Grossman SR, Stratakis CA, Boikos SA. Gastrointestinal stromal tumors: the GIST of Precision Medicine. Trends Cancer. 2018;4(1):74–91.
Rizzo A, Pantaleo MA, Astolfi A, Indio V, Nannini M. The identity of PDGFRA D842V-Mutant gastrointestinal stromal tumors (GIST). Cancers (Basel) 2021, 13(4).
Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83.
Doyle LA, Hornick JL. Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase. Histopathology. 2014;64(1):53–67.
Nannini M, Urbini M, Astolf A, Biasco G, Pantaleo MA. Erratum to: the Progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). J Transl Med. 2017;15(1):125.
Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 2010;14(1–2):42–50.
Rubin BP, Heinrich MC. Genotyping and immunohistochemistry of gastrointestinal stromal tumors: an update. Semin Diagn Pathol. 2015;32(5):392–9.
Mulet-Margalef N, Garcia-Del-Muro X. Sunitinib in the treatment of gastrointestinal stromal Tumor: patient selection and perspectives. Onco Targets Ther. 2016;9:7573–82.
Li K, Cheng H, Li Z, Pang Y, Jia X, Xie F, Hu G, Cai Q, Wang Y. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget. 2017;8(36):60589–604.
Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, et al. Risk of recurrence of gastrointestinal stromal tumour after Surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–74.
Barnett CM, Corless CL, Heinrich MC. Gastrointestinal stromal tumors: molecular markers and genetic subtypes. Hematol Oncol Clin North Am. 2013;27(5):871–88.
Schaefer IM, DeMatteo RP, Serrano C. The GIST of advances in treatment of Advanced Gastrointestinal Stromal Tumor. Am Soc Clin Oncol Educ Book. 2022;42:1–15.
Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. RKIP: much more than raf kinase inhibitory protein. J Cell Physiol. 2013;228(8):1688–702.
Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol. 2000;20(9):3079–85.
Yesilkanal AE, Rosner MR. Raf kinase inhibitory protein (RKIP) as a Metastasis suppressor: regulation of signaling networks in cancer. Crit Rev Oncog. 2014;19(6):447–54.
Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001;21(21):7207–17.
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.
Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets. 2008;12(10):1275–87.
Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of Prostate cancer Metastasis. J Natl Cancer Inst. 2003;95(12):878–89.
Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with Breast cancer Metastasis. Clin Cancer Res. 2005;11(20):7392–7.
Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A. Loss of raf-1 kinase inhibitor protein expression is associated with Tumor progression and Metastasis in Colorectal cancer. Am J Clin Pathol. 2007;127(5):820–7.
Kim HS, Kim GY, Lim SJ, Kim YW. Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr Pathol. 2010;21(4):253–7.
Kim HS, Kim GY, Lim SJ, Kim YW. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology. 2010;42(7):655–60.
Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott L, Fyfe N, Murray GI, et al. Raf kinase inhibitor protein expression in a survival analysis of Colorectal cancer patients. J Clin Oncol. 2006;24(36):5672–9.
Xu YF, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, Cai MY, Ju MJ, Zhou J, Zhang BH, et al. PEBP1 downregulation is associated to poor prognosis in HCC related to Hepatitis B Infection. J Hepatol. 2010;53(5):872–9.
Chatterjee D, Sabo E, Tavares R, Resnick MB. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res. 2008;14(10):2994–3001.
Akaishi J, Onda M, Asaka S, Okamoto J, Miyamoto S, Nagahama M, Ito K, Kawanami O, Shimizu K. Growth-suppressive function of phosphatidylethanolamine-binding protein in anaplastic thyroid cancer. Anticancer Res. 2006;26(6B):4437–42.
Zhang L, Fu Z, Binkley C, Giordano T, Burant CF, Logsdon CD, Simeone DM. Raf kinase inhibitory protein inhibits beta-cell proliferation. Surgery. 2004;136(3):708–15.
al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst. 2011;7(3):928–41.
Bement WM. A role for RKIP in cell motility. Chem Biol. 2005;12(9):953–4.
Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic Prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of snail repression and RKIP induction. Oncogene. 2009;28(40):3573–85.
Hellmann J, Rommelspacher H, Muhlbauer E, Wernicke C. Raf kinase inhibitor protein enhances neuronal differentiation in human SH-SY5Y cells. Dev Neurosci. 2010;32(1):33–46.
Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z. Effects of raf kinase inhibitor protein expression on Metastasis and progression of human Breast cancer. Mol Cancer Res. 2009;7(6):832–40.
Martinho O, Gouveia A, Silva P, Pimenta A, Reis RM, Lopes JM. Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch. 2009;455(3):277–84.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–65.
Campanella NC, Celestino R, Pestana A, Scapulatempo-Neto C, de Oliveira AT, Brito MJ, Gouveia A, Lopes JM, Guimaraes DP, Soares P, et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur J Hum Genet. 2015;23(6):877–9.
de Oliveira AT, Pinheiro C, Longatto-Filho A, Brito MJ, Martinho O, Matos D, Carvalho AL, Vazquez VL, Silva TB, Scapulatempo C, et al. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr. 2012;44(1):171–8.
de Oliveira AT, Reis RM, Afonso J, Martinho O, Matos D, Carvalho AL, Vazquez VL, Silva TB, Scapulatempo C, Saad SS, et al. Lymphangiogenic VEGF-C and VEGFR-3 expression in genetically characterised gastrointestinal stromal tumours. Histol Histopathol. 2011;26(12):1499–507.
Gomes INF, da Silva-Oliveira RJ, da Silva LS, Martinho O, Evangelista AF, van Helvoort Lengert A, Leal LF, Silva VAO, Dos Santos SP, Nascimento FC et al. Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell lines. Cells 2022, 11(1).
Martinho O, Silva-Oliveira R, Miranda-Goncalves V, Clara C, Almeida JR, Carvalho AL, Barata JT, Reis RM. In Vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in Glioblastomas. Transl Oncol. 2013;6(2):187–96.
Silva VAO, Rosa MN, Gomes INF, Vital PDS, Alves ALV, Evangelista AF, Longato GB, Carloni AC, Oliveira BG, Pinto FE et al. Bio-prospecting of Crude Leaf extracts from thirteen plants of Brazilian Cerrado Biome on Human Glioma Cell lines. Molecules 2023, 28(3).
Silva-Oliveira RJ, Lopes GF, Camargos LF, Ribeiro AM, Santos FV, Severino RP, Severino VG, Terezan AP, Thome RG, Santos HB et al. Tapirira Guianensis Aubl. Extracts inhibit Proliferation and Migration of Oral Cancer cells lines. Int J Mol Sci 2016, 17(11).
Menezes WP, Silva VAO, Gomes INF, Rosa MN, Spina MLC, Carloni AC, Alves ALV, Melendez M, Almeida GC, Silva LSD et al. Loss of 5’-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness. Cells 2020, 9(2).
Leal LF, Evangelista AF, de Paula FE, Caravina Almeida G, Carloni AC, Saggioro F, Stavale JN, Malheiros SMF, Mancano B, de Oliveira MA, et al. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Neuropathology. 2018;38(5):475–83.
Evangelista AF, Zanon MF, Carloni AC, de Paula FE, Morini MA, Ferreira-Neto M, Soares IC, Miziara JE, de Marchi P, Scapulatempo-Neto C, et al. Detection of ALK fusion transcripts in FFPE Lung cancer samples by NanoString technology. BMC Pulm Med. 2017;17(1):86.
Waggott D, Chu K, Yin S, Wouters BG, Liu FF, Boutros PC. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012;28(11):1546–8.
Thome CH, Ferreira GA, Pereira-Martins DA, Augusto Dos Santos G, Almeida-Silveira DR, Weinhauser I, Antonio de Souza G, Houtsma R, Schuringa JJ, Rego EM, et al. The expression of NTAL and its protein interactors is Associated with Clinical outcomes in Acute Myeloid Leukemia. Mol Cell Proteomics. 2021;20:100091.
Castillo MJ, Reynolds KJ, Gomes A, Fenselau C, Yao X. Quantitative protein analysis using enzymatic [(1)(8)O]water labeling. Curr Protoc Protein Sci. 2014;76:23. 24 21–23 24 29.
Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics. 2006;5(1):144–56.
Cessna H, Baritaki S, Zaravinos A, Bonavida B. The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment. Cancers (Basel) 2022, 14(19).
Valadao M, Braggio D, Santos AF, Pimenta-Inada HK, Linhares E, Goncalves R, Romano S, Vilhena B, Small I, Cubero D, et al. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients. J Surg Res. 2012;178(1):288–93.
Schoppmann SF, Beer A, Nirtl N, Ba-Ssalamah A, Brodowicz T, Streubel B, Birner P. Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway. Cancer Lett. 2013;335(1):26–30.
Wang Y, Chen JJ, Wang XF, Wang Q. Clinical and prognostic significance of raf kinase inhibitory protein expression in gastrointestinal stromal tumors. World J Gastroenterol. 2018;24(23):2508–17.
Zaravinos A, Bonavida B, Chatzaki E, Baritaki S. RKIP: a Key Regulator in Tumor Metastasis initiation and resistance to apoptosis: therapeutic targeting and impact. Cancers (Basel) 2018, 10(9).
Yu M, Wang Q, Ding JW, Yang Z, Xie C, Lu NH. Association between raf kinase inhibitor protein loss and prognosis in cancers of the digestive system: a meta-analysis. Cancer Biomark. 2014;14(5):389–400.
Kim HS, Park SJ, Lee KY, Park YK, Kim YW. Reduced Raf-1 kinase inhibitor protein expression predicts less favorable outcomes in patients with hepatic colorectal Metastasis. Oncol Rep. 2012;28(1):161–71.
Huerta-Yepez S, Yoon NK, Hernandez-Cueto A, Mah V, Rivera-Pazos CM, Chatterjee D, Vega MI, Maresh EL, Horvath S, Chia D, et al. Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of Lung cancer survival. BMC Cancer. 2011;11:259.
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and Disease. Nat Rev Mol Cell Biol. 2014;15(12):786–801.
Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15(12):1243–53.
Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395–406.
Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour Metastasis. Nat Rev Cancer. 2014;14(6):430–9.
Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van’t Veer LJ, Bartelink H, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting Breast cancer survival. Proc Natl Acad Sci U S A. 2005;102(10):3738–43.
Yuan L, Shu B, Chen L, Qian K, Wang Y, Qian G, Zhu Y, Cao X, Xie C, Xiao Y, et al. Overexpression of COL3A1 confers a poor prognosis in human Bladder cancer identified by co-expression analysis. Oncotarget. 2017;8(41):70508–20.
Wang XQ, Tang ZX, Yu D, Cui SJ, Jiang YH, Zhang Q, Wang J, Yang PY, Liu F. Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinoma. Oncotarget. 2016;7(8):8823–38.
Zhang H, Ding C, Li Y, Xing C, Wang S, Yu Z, Chen L, Li P, Dai M. Data mining-based study of collagen type III alpha 1 (COL3A1) prognostic value and immune exploration in pan-cancer. Bioengineered. 2021;12(1):3634–46.
Fernandez-Serra A, Moura DS, Sanchez-Izquierdo MD, Calabuig-Farinas S, Lopez-Alvarez M, Martinez-Martinez A, Carrasco-Garcia I, Ramirez-Calvo M, Blanco-Alcaina E, Lopez-Reig R et al. Prognostic impact of let-7e MicroRNA and its target genes in localized high-risk intestinal GIST: a Spanish Group for Research on Sarcoma (GEIS) Study. Cancers (Basel) 2020, 12(10).
Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, Liang H, Li WH, Ishwaran H, Minn AJ, et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic Breast cancer. EMBO J. 2011;30(21):4500–14.
Warnatz HJ, Schmidt D, Manke T, Piccini I, Sultan M, Borodina T, Balzereit D, Wruck W, Soldatov A, Vingron M, et al. The BTB and CNC homology 1 (BACH1) target genes are involved in the oxidative stress response and in control of the cell cycle. J Biol Chem. 2011;286(26):23521–32.
Add Comment